Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (iparomlimab + tuvonralimab) plus GemCis in first-line biliary tract cancers
ChiCTR2500105911Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 1 more, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2500105911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105911.